Clinical profile of ITP in Children: A single center study

Similar documents
Neutropenia Following Intravenous Immunoglobulin Therapy in Pediatric Patients with Idiopathic Thrombocytopenic Purpura

Management of Acute ITP in Children Fifteen Years Experience

Original Article Epidemiology of Idiopathic Thrombocytopenic Purpura in Children

Evaluation of clinical characteristics, diagnosis and management in childhood immune thrombocytopenic purpura: a single center s experience

Contemporary perspectives and initial management of pediatric ITP. William Beau Mitchell, MD Weill Cornell Medical College New York, NY USA

High Remission Rate of Chronic Immune Thrombocytopenia in Children: Result of 20-Year Follow-Up

V.N. KARAZIN KHARKOV NATIONAL UNIVERSITY

INTRODUCTION TO SET FORTH APROACH TO MANAGING ADULTS TO SET FORTH APROACH PRIMARY ( PRIMARY AUTOIMMUNE) AUTOIMMUNE ITP FROM ASH & THE BRITISH

Case Report Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist

Remissions after long term use of romiplostim for immune thrombocytopenia

Acute Immune Thrombocytopenic Purpura (ITP) in Childhood

Developed by Stephanie Zachary, Sarah Weicker, Dr. Jeremy Friedman, Dr. Carolyn Beck, and Dr. Lauren Kitney for PedsCases.com.

Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura Kumar M, Vik T A, Johnson C S, Southwood M E, Croop J M

Long-term results of laparoscopic splenectomy in pediatric chronic immune thrombocytopenic purpura

Idiopathic thrombocytopenic purpura in children: A 10 years experience at tertiary care hospital

abstract conclusions A four-day course of high-dose dexamethasone is effective initial therapy for adults with immune thrombocytopenic purpura.

ABSTRACT Background High-dose intravenous immune globulin produces a temporary rise in the platelet count

Idiopathic Thrombocytopenic Purpura

Clinical Variables among Adult Patients with Chronic Idiopathic Thrombocytopenic Purpura in West Iran

QUICK REFERENCE Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)

Expert Review: Updates in Immune Thrombocytopenia. Reference Slides

ASH Draft Recommendations for Immune Thrombocytopenia

The Turkish Journal of Pediatrics 2010; 52:

MMR vaccine and idiopathic thrombocytopaenic purpura

Evolution of clinical guidelines for ITP: Role of Romiplostim

Pediatric Immune Thrombocytopenia (ITP) Cindy E. Neunert MD, MSCS Associate Professor, Pediatrics Columbia University Medical Center New York, NY

Platelet Disorders. By : Saja Al-Oran

A CLINICAL STUDY OF PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA

Acute Immune Thrombocytopenic Purpura in Infants

Thrombocytopenia: a practial approach

Guidelines for Shared Care Centres and Community Staff

GOOD MORNING! Thursday, July Heidi Murphy, MD Leslie Carter-King, MD

CANADIAN COST-UTILITY ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN FOR ACUTE CHILDHOOD IDIOPATHIC THROMBOCYTOPENIC PURPURA

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data

Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph

Scottish Medicines Consortium

Promacta (eltrombopag)

Treatment pathway for adult patients with immune (idiopathic) thrombocytopenic purpura (ITP)

Original Article Iran J Ped Hematol Oncol. 2016, Vol6.No2,

The role of oral hygiene in a patient with idiopathic thrombocytopenic purpura

Immune Thrombocytopenia (ITP)

Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014

Scottish Medicines Consortium

Dr. Rai Muhammad Asghar Associate Professor Head of Pediatric Department Rawalpindi Medical College

eltrombopag (Promacta )

When and how to treat childhood immune

Cigna Drug and Biologic Coverage Policy

EDUCATIONAL COMMENTARY PLATELET DISORDERS

Revolade Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP

Idiopathic Thrombocytopenic Purpura Presenting as Post-extraction Hemorrhage

3/21/2016. Immune Thrombocytopenia. My Background. Objectives. Case Study. Case Study. No disclosures. Rochelle Boote, MD 4/8/2016

Abnormal blood counts in children Dr Tina Biss Consultant Paediatric Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust

Pharmacy Prior Authorization

Bleeding Disorders.2 MS Abdallah Awidi Abbadi.MD. FRCP.FRCPath Feras Fararjeh MD

Authors: Shuling Li, PhD 1, Julia Molony, MS 1, Karynsa Cetin, MPH 2, Jeffrey Wasser, MD 3, Ivy Altomare, MD 4

CLINICAL PROFILE REVIEW OF PATIENTS WITH THROMBOCYTOPENIA: A STUDY OF 100 CASES AT A TERTIARY CARE CENTRE

REVIEW Controversies in the Diagnosis and Management of Childhood Acute Immune Thrombocytopenic Purpura

Immune Thrombocytopenia among Children Living at a High Altitude Region: A Hospital-Based Retrospective Study

The Role of Anti-D in the Management of Chronic and Secondary Forms of ITP

For platelet control as individual as you

Description of the evidence collection method. (1). Each recommendation was discussed by the committee and a consensus

Use of Intravenous Anti-RhD Immunoglobulin (RhIG) in the Treatment of Primary Immune Thrombocytopenia

Second line therapy for ITP should be TPO agonists. Nichola Cooper Imperial Health Care NHS Trust

Promacta. Promacta (eltrombopag) Description

thrombopoietin receptor agonists and University of Washington January 13, 2012

The use of splenic artery embolisation as a bridge to safe laparoscopic splenectomy in a patient with resistant immune thrombocytopenic purpura

Rituximab for the treatment of adults with idiopathic (immune) thrombocytopenic purpura (ITP)

What is the next step after failure of steroids in ITP? Splenectomy & Rituximab

Clinical Commissioning Policy Proposition: Rituximab for cytopaenia complicating primary immunodeficiency

Bleeding disorders. Hemostatic failure: Inappropriate and excessive bleeding either spontaneous or in response to injury.

HEME 10 Bleeding Disorders

PRESCRIBING GUIDELINE CONTROL PAGE. Title: Suspected or known Immune Thrombocytopenia Management Plan (Children) Version: 1 Reference Number: MMC-G117

Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP)

Thrombotic Thrombocytopenic

The importance of thrombocytopenia and its causes

The ITP Patient Advocate

Diagnosis and Management of Immune Thrombocytopenias. Thomas L. Ortel, M.D., Ph.D. Duke University Medical Center 2 November 2016

Case Report. Idiopathic Thrombocytopenic Purpura: Overview And Report Of Two Cases.

BLEEDING (PLATELET) DISORDER. IAP UG Teaching slides

THE OLD AND THE NEW OF ITP. Alison Street Malaysia April 2010

Shunpei Hama, 1 Fumiaki Inori, 1 Dai Momose, 2 and Sadahiko Konishi Introduction. 2. Case Report

Il Rituximab nella ITP

Personal Practice. Immune Thrombocytopenic Purpura

Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children

2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?

Assessing thrombocytopenia in the intensive care unit: The past, present, and future

PROMACTA (eltrombopag olamine) oral tablet and oral suspension

Splenectomy for immune thrombocytopenic purpura

Promacta. Promacta (eltrombopag) Description

Laparoscopic Splenectomy Optimal Solution in Autoimmune Trombocytopenic Purpura

Most Common Hemostasis Consults: Thrombocytopenia

Reactive thrombocytosis in children

Haemostasis & Coagulation disorders Objectives:

Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura

Dr Kannan S Consultant Hematologist Sahyadri Speciality Hospital, Pune K E M Hospital, Pune

Technology appraisal guidance Published: 27 April 2011 nice.org.uk/guidance/ta221

We Can Cure Chronic Lymphocytic Leukemia with Current / Soon to be Approved Agents: CON ARGUMENT

Lupus Erythematosus - Can Anti-SS-A Antibody Predict the Next Event?

Cover Page. The handle holds various files of this Leiden University dissertation

Pharmacy Prior Authorization

Transcription:

Clinical profile of ITP in Children: A single center study Dr.Ramadan Allalous 1,Dr Fathia Alriani 1, Dr Amna Rayani 2. 1Tripoli ' s Medical center,medical Faculty, Tripoli University 2Tripoli Children Hospital, Medical Faculty, Tripoli University amnnarayani@yahoo.com :author: Amna Rayani, E mail Correspondent Abstract BACKGROUND: Idiopathic thrombocytopenia (ITP) is the most common bleeding disorder in children, characterized by immune mediated platelets destruction. Objective: The aim is to determine the clinical features, treatment and outcomes of children with ITP. PATIENTS AND METHODS: The files of 165 pediatric patients diagnosed and treated between January 1997 and September 2005 were retrospectively reviewed; data abstracted including age, gender, presenting clinical features, laboratory findings and treatment outcome. RESULTS: They were 98 males and 67 females patients (M:F) (1.5:1).The median age was 4 years and 6 months with a range between 1.5months -15 years. The most common presenting features were purpura in 92.7%, epistaxis 37%, and gum bleeding 17.5%. One hundred fifteen (70%) of the patients had platelets count less than 20.000/µl. One hundred fifty one Patients (94%) were treated. Steroids was given to 123 Patients with 89% response rate (110 patients), 13 patients did not respond to steroid therapy. Out of the 110 patient responded to steroid only 74 patient thrombocytes count had sustained the response to steroids. IVIG was given to 61 Patients. Forty six patients (75%) had a good response to IVIG but only 21 patients had a sustained response. Combined treatment of steroid and IVIG was given to 57 Patients, only 25 patients (28%) had response and none of them had sustained response. The 57patients had combined therapy were; 29 had combined steroid and IVIG from the start, while the other 28 patients were 13 patients who had steroid and they did not respond, and the other 15 patients had IVIG only but did not showed response. Nine patients had Splenectomy, 7patients (77.8%) responded and only two patients did not show response. One hundred fifty one (94%) Patients recovered within 4-8 weeks, 43 (26%) developed chronic ITP (persistent more than 6 months), nine children underwent splenectomy and was curative in 7 patients. Nine Patients recovered spontaneously, 11 patients have persistent thrombocytopenia, and 13 patients were lost follow up. Overall, 140 patients (85%) of 165 children recovered completely.

CONCLUSION: Acute and chronic ITP in children are generally benign condition. Treatment decisions should follow guide line based on the clinical picture and platelets Key words ITP in children, Splenectomy, Steroid, IVIG, Chronic ITP INTRODUCTION: Idiopathic thrombocytopenic purpura (ITP) in children is usually a self- limiting disorder. It manifests typically as isolated thrombocytopenia and mucocutaneous bleeding. It is usually preceded by viral infection or immunization and by the time of diagnosis most children have recovered from their viral symptoms. Although ITP is most common between 2 and 5 years of age, it occurs in all pediatric age groups (1). The incidence is about 4 per 100,000 children per year (2). Most children remit spontaneously within six to eight weeks and have only cutaneous or mild bleeding. (3) Intracranial hemorrhage (ICH) is extremely rare with the incidence of about 1% (2), but it is the major cause of death in children with ITP. (4) Persistent (Chronic) ITP is defined as the documented persistence of thrombocytopenia for more than 6 months from initial presentation. (7) Treatment to raise the platelet count, even when profoundly low, is not always count. Splenectomy should be considered in chronic ITP with significant bleeding and for patients did not respond to medical treatment. required, options include steroids, intravenous immunoglobulin (IVIG), anti- D and immunosuppression drugs. (5,6) Splenectomy is rarely required and should be reserved for those who have both chronic ITP and significant bleeding problems. (7) Chronic ITP is defined as the documented persistence of thrombocytopenia for more than 6 months from initial presentation. (8) Method This retrospective study was carried out at the hematology pediatric outpatient clinic in the Tripoli Medical Center. We have reviewed the medical files of 165 pediatric patients diagnosed and treated for acute and chronic ITP between January 1997 and September 2005. Data abstracted include age, gender, and history of immunization, history of viral infection, presenting clinical features, laboratory findings, treatment and outcomes.

Result One hundred sixty five patients were identified in this retrospective study. There were 98 (60%) male and 67 (40%) female (m: f = 1.5:1). Figure 1. The median age was 4.5 years with range (1.5 months 15 years). Figure 1. Sex distribution of children with ITP The most common presenting features were purpura 153 (92.7%) manifested as petechial rash and /or ecchymosis; 61 patients (36.9%) presented with epistaxis, 29 patients (17.5%) with gum bleed, 6 patients (3.7%) with hematuria and one child with bloody diarrhea. Acute viral illness preceding this illness was reported in forty-seven children (28%) of ITP patients in this study. Majority of the cases (97%) have platelet count less than 20,000/μL with the mean 13,000/µL and most of the cases were diagnosed by clinical features and peripheral blood film. Few cases underwent which was normal. a bone marrow examination Overall 140 patients (84%) recovered completely. One hundred fifty one patients received treatment. Steroids are given to (123) patients with response rate of (89.4%). Sustained response to a single course of steroids in (59.3%), and (30%) were initially responded then relapsed when steroids reduced or stopped. IVIG in (61) patients out of them 46 patients responded (75.4%), 21patients (34.4%) sustained response and 25 (40.9%) relapsed after initial response. Combined treatment in (57) patients with 25/57 (43.8%) response rate, 14 (1.4%) patients recovered spontaneously. Ninety four patients (57%) recovered within 4 to 8 weeks. Forty three patients (25%) developed chronic ITP ( persistent > 6 months), of these 9 patients underwent Splenectomy and was curative in 7 ( 77.7%) patients, 9 patients recovered, 11 patients have persistent thrombocytopenia, one patient died due to CNS bleeding and 13 patients were lost for follow up. No response Sustained response Response Total number Treatment 13 73 )%89( 110 123 Steroids 15 21 )%75( 46 61 IVIG 32 - )%28( 25 57 multiple 2 - )%77.8( 7 9 splenectomy Table (1) response of treatment of ITP

DISCUSSION ITP is one of the most commonly acquired bleeding disorders. Usually it is not serious and most children improve within weeks to months. Our result showed 29% of cases preceded by viral illness. Data about immunization were not available.in our study, the median age was 4.5 years range (1.5mo.-15 yrs.) slightly younger compared to other studies (12,13), and more common in males (60%). Most patients presented with purpura (92.7%), epistaxis (36.9%), gum bleeding (17.5%) and hematuria (3.7%). The majority of the cases in our study diagnosed by clinical features and blood film, only few cases underwent a bone marrow examination but it did not alter the diagnosis, as reported by others (13). Most children remit spontaneously within six to eight weeks and have only cutaneous or mild bleeding (3), but in our study only fourteen children remit spontaneously because the majority of children needed treatment at presentation. Corticosteroids treatment in ITP, increase the platelet count in about 80% of patients (10). In this study, 123 children received steroid, of those, 110 (89.4%) responded. This result supported Waits reported data (13). Most of the children recovered before 6 months from diagnosis. In our study 43 (25%) of children developed chronic ITP (persistent >6 months) in contrast to a much higher incidence in another study (57%) in a cohort described by lower et al (9). Out of these 42 patients, nine children had normal platelets counts, thirteen children missed follow up, eleven children still under follow up with low platelet, one child died due to intracranial hemorrhage. Furthermore, nine children underwent Splenectomy; seven of them responded (77.8%). ITP response to Splenectomy in this study was different significantly from George et al reported result in 271 children who had elective Splenectomy for chronic ITP. (14) The American Society of Hematology (ASH) practice guidelines recommended that Splenectomy be considered for children in whom ITP has persisted for at least one year, and who have symptoms of bleeding and a platelet count less than 10,000/uL ( ages 3 to 12 years) of 10,000 to 30,000/uL (ages 8 12 years)(14). In this study, all patients who was treated either had symptoms or signs suggestive bleeding or/and severe thrombocytopenia. Conclusion ITP in children has a good prognosis. Only a small number of children end up with chronic type of the disease. Severe thrombocytopenia and serious bleeding is not common. Giving treating is usually based upon clinical feature. Either of the

treatment modalities can be used, but in severe and unresponsive cases to steroid and/or IVIG, Splenectomy can be effective in some resistant cases. REFERENCES 1. Nugent DJ.CHILDREN immune thrombocytopenic purpura. Blood Rev 2002; 16:27-29. 2. Lilleyman JS. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 1999; 105: 871-5. 3. Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet 1997; 350:620-3. 4. Lilleyman JS. Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Pediatric Haematology forum of the British Society for Haematology Arch Dis child 1994; 71:251-3. 5. Vesely S. Buchanan G. Cohen A, Raskob G, George J. self reported diagnostic and management strategies n childhood idiopathic thrombocytopenic purpura results of a survey of practicing pediatric haematology-oncology specialist. Pediatric Hematol oncol 2000; 22:55-61. 6. Eden OB Lilleyman JS. Guidelines for management of Idiopathic thrombocytopenic purpura. The British Paediatric Hematology Group.Arch Dis Child 1992; 67: 1056-8. 7. Tamary H. Kaplinsky c, Levy I. et al. Chronic childhood idiopathic thrombocytopenic purpura. Long term follow up. Acta Paediatric 1994; 83:931-4. 8. Chessells J. Chronic Idiopathic thrombocytopenic purpura : prim in non noceere Arch Dis Child 1989; 64:1326-8. 9. Taub JW, Warrier I, Holtkamp C. Beardsley DS, Lusher JM. Characterization of autoantibodies against the platelet glycoprotein antigens. Ib/IIIa in childhood idiopathic thrombocytopenic pupura. AM J Hematol 1995; 48:104-7. 10. Mc Verry BA Management of Idiopathic thrombocytopenic purpura Br. J Hematol 1985; 59:203-8. 11. Lowe EJ, Buchanan GR. Idiopathic thrombocytopenic purpura diagnosed during the second decade of life. J Pediatric 2002; 141:253-258. 12. El Alfy MS. Mkhtar GM, El-Laboudy MA, Khalifa AS. Acta Haematol. 2006; 115 (1-2): 46-52. 13. Watts RG Clin Pedia (Phila). 2004 Oct. 43 (8): 691-702. 14. George JN, Woolf SH, Raskob GE, et al: Idiopathic thrombocytopenic purpura: A practice guideline developed by eplicit methods for the American: society of Hematology, Blood 1996; 88:3.